Rochester, MNNCT06676579Now EnrollingIRB Ready

IgA Nephropathy Clinical Trial in Rochester, MN

Access cutting-edge iga nephropathy treatment through this phase 2 clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Rochester location

Preparing your pre-screening questions…

Expert Care in Rochester

Access iga nephropathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related iga nephropathy treatment provided free

Apply for This Rochester Location

Check if you qualify for this iga nephropathy clinical trial in Rochester, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Rochester

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Rochester site if eligible
  4. 4Begin participation

About This IgA Nephropathy Study in Rochester

The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Age \> 18 years
Kidney biopsy showing crescentic IgA nephropathy within 6 months of enrolment (MEST-C-score =C1/C2).
Quantified creatinine clearance \>20 ml/min/1.73m2
Quantified Proteinuria \> 750 mg/24h based on a 24h urine collection while on maximum tolerated dose of RAS blockade
Hematuria defined as \>10 RBC/hpf or hemoglobinuria \>1+
Patients need to be in adequate supportive care (blood pressure \<125/85mmHg, lifestyle advice, and maximum doses tolerable of RAS blockade) at least 4 weeks prior to enrollment
Patients would receive dietary and lifestyle counseling prior enrollment: low protein (0.8-1.0 g/kg/day) diet, low sodium (2 grams/day) intake, indication for smoke cessation, during the 4 weeks run-in period
Has signed an informed consent form prior to any study-related procedures
Patients with documented use of RAS blockade and adequate blood pressure control (\<125/85 mmHg) for ≥4 weeks, can be enrolled in the study and randomized without repeating a 4-week run-in period.

Exclusion Criteria

Creatinine clearance \<20 ml/min/1.73 m2
Liver function tests \> 2x upper limit of normal. (Serious cases of hepatotoxicity have been reported in patients with avacopan during first approval and ADVOCATE study (29) (30)
Severe interstitial fibrosis and tubular atrophy (IFTA \> 70% on renal biopsy)
Active cancer or acute non-controlled infection (including HIV, HBV, HCV)
Women who are pregnant or breastfeeding
Immunosuppression treatment:
Rituximab less than 12 months prior to enrollment
MMF, CYC, or immunomodulatory agents within 3 months prior to enrollment
AZA within 3 months prior to enrollment.
Glucocorticoids \>20 mg/day within 1 month prior to enrollment
Secondary IgA nephropathy (associated with gastrointestinal diseases, infection, autoimmune, malignancy, respiratory tract, or skin)
ANCA-associated vasculitis or other vasculitis diagnostic defined by ACR criteria/Chapel Hill Consensus conference
Contraindication to use any of the protocol treatments (glucocorticoids, avacopan)
Use of a strong/moderate CYP3A4 inducer
Initiation of SGLT2 inhibitors is not allowed once patient has been enrolled in the study. Patients who have been on an SGLT2 inhibitor prior to enrollment on the study may continue on this therapy, at the same dose. No dose increase is allowed.
Active, untreated and/or uncontrolled chronic liver disease (chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis, cirrhosis
Unable to give written consent form
As a safety measure patients who are pregnant or lactating will not be enrolled in the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT06676579) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

IgA Nephropathy Treatment Options in Rochester, MN

If you're searching for iga nephropathy treatment options in Rochester, MN, this clinical trial (NCT06676579) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced iga nephropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all iga nephropathy clinical trials near you to find additional studies recruiting in your area.

More IgA Nephropathy Trials in Rochester, MN

See all iga nephropathy clinical trials recruiting in Rochester — not just this study.

Browse IgA Nephropathy Trials in Rochester →

Browse More Trials by Condition

IgA Nephropathy TrialsPulmonary Hypertension TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Rochester?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Rochester, MN